Futuximab

Summary

Futuximab (CHEMBL2109388) is a phase-3 clinical-stage antibody; indicated across 4 conditions including squamous cell carcinoma and glioma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 4 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109388
Name	Futuximab
Type	Antibody
Max phase	3

Also known as: 992 DS, Futuximab, SYM-004, Sym004, FUTUXIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
squamous cell carcinoma	2	MONDO:0005096	EFO:0000707
glioma	2	MONDO:0021042	MONDO:0100342
neoplasm	1	MONDO:0005070	EFO:0000616
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1/PHASE2	3
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03717038	PHASE3	WITHDRAWN	Sym004 Versus TAS-102 in Patients With mCRC
NCT05223673	PHASE3	TERMINATED	Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
NCT01117428	PHASE1/PHASE2	COMPLETED	Sym004 in Patients With Advanced Solid Tumors
NCT01417936	PHASE2	COMPLETED	Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
NCT02083653	PHASE2	COMPLETED	Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
NCT02568046	PHASE1/PHASE2	TERMINATED	Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
NCT02924233	PHASE1/PHASE2	WITHDRAWN	Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
NCT02965417	PHASE2	WITHDRAWN	Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
NCT03549338	PHASE2	TERMINATED	Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
NCT01955473	PHASE1	COMPLETED	Japanese Phase 1 Trial of Sym004 in Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).